Public COmpany Profiles
Startups developed from Yale’s cutting edge academic research are in areas ranging from life sciences, biotechnology, digital health, and climate technology. Many of these companies call Connecticut home. Five will be presenting updates at the 2023 Yale Innovation Summit.
June 1: 3:30 PM - 4:30 PM
(NASDAQ: ARVN)
Arvinas is a clinical-stage, New Haven based, biotechnology company. Arvinas will provide an overview of its PROTAC® protein degradation platform and the progress made over the 10 years since its founding, including multiple preclinical and clinical programs. Arvinas currently has three compounds in late-stage clinical development, including one phase 3 trial and two additional phase 3 trials on-track to initiate in the second half of 2023. The Company is also on track to submit an Investigational New Drug Application (IND) or Clinical Trial Authorization (CTA) for two new compounds in 2023 – including its first in neuroscience - with two additional compounds in IND/CTA-enabling studies by the end of the year.
May 31, 10:00 AM - 4:30 PM
(NYSE: BHVN)
Biohaven is a modern pharmaceutical company, headquarted in New Haven, that is guided by science and inspired to change the lives of people with unmet medical needs. This event is invite-only.
June 1, 2:30 PM - 3:30 PM
(NASDAQ: HYPR)
Hyperfine is the groundbreaking MedTech company, based in Guilford, that created Swoop, the world’s first FDA-cleared portable magnetic resonance imaging (MRI) system capable of providing neuroimaging at the point of care.
June 1, 9 AM - 10 AM
(NASDAQ: RLYB)
Rallybio is a clinical-stage biotechnology company based in New Haven, built around a team of seasoned industry leaders.
June 1, 10:30 AM - 12:00 PM
(NASDAQ: TRVI)
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, based in New Haven. Trevi will provide an in-depth discussion on its chronic cough programs, with a specific focus on the translatability of Haduvio’s mechanism across various cough conditions as well as a deeper dive into commercial aspects of the indications. Trevi will be joined by one of the thought leaders in cough, Peter Dicpinigaitis, MD, who will discuss the pathways in cough and the importance of a centrally active mechanism.